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Abstract
To investigate the underlying mechanisms of T2D pathogenesis, we looked for diabetes susceptibility genes that increase
the risk of type 2 diabetes (T2D) in a Han Chinese population. A two-stage genome-wide association (GWA) study was
conducted, in which 995 patients and 894 controls were genotyped using the Illumina HumanHap550-Duo BeadChip for
the first genome scan stage. This was further replicated in 1,803 patients and 1,473 controls in stage 2. We found two loci
not previously associated with diabetes susceptibility in and around the genes protein tyrosine phosphatase receptor type
D( PTPRD)( P=8.54610
210; odds ratio [OR]=1.57; 95% confidence interval [CI]=1.36–1.82), and serine racemase (SRR)
(P=3.06610
29; OR=1.28; 95% CI=1.18–1.39). We also confirmed that variants in KCNQ1 were associated with T2D risk, with
the strongest signal at rs2237895 (P=9.65610
210; OR=1.29, 95% CI=1.19–1.40). By identifying two novel genetic
susceptibility loci in a Han Chinese population and confirming the involvement of KCNQ1, which was previously reported to
be associated with T2D in Japanese and European descent populations, our results may lead to a better understanding of
differences in the molecular pathogenesis of T2D among various populations.
Citation: Tsai F-J, Yang C-F, Chen C-C, Chuang L-M, Lu C-H, et al. (2010) A Genome-Wide Association Study Identifies Susceptibility Variants for Type 2 Diabetes in
Han Chinese. PLoS Genet 6(2): e1000847. doi:10.1371/journal.pgen.1000847
Editor: Peter M. Visscher, Queensland Institute of Medical Research, Australia
Received June 25, 2009; Accepted January 18, 2010; Published February 19, 2010
Copyright:  2010 Tsai et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by Academia Sinica Genomic Medicine Multicenter Study; National Research Program for Genomic Medicine, National
Science Council, Taiwan (National Clinical Core, NSC97-3112-B-001-014; and National Genotyping Center, NSC97-3112-B-001-015). The funders had no role in
study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: chen0010@ibms.sinica.edu.tw (Y-TC); jywu@ibms.sinica.edu.tw (J-YW)
. These authors contributed equally to this work
Introduction
Type 2 diabetes (T2D) affects at least 6% of the world’s
population; the worldwide prevalenceis expected to double by 2025
[1]. T2D is a complex disorder that is characterized by
hyperglycemia, which results from impaired pancreatic b cell
function, decreased insulin action at target tissues, and increased
glucose output by the liver [2]. Both genetic and environmental
factors contribute to the pathogenesis of T2D. The disease is
considered to be a polygenic disorder in which each genetic variant
confers a partial and additive effect. Only 5%–10% of T2D cases
are due to single gene defects; these include maturity-onset diabetes
of the young (MODY), insulin resistance syndromes, mitochondrial
diabetes, and neonatal diabetes [3–5]. Inherited variations have
been identified from studies of monogenic diabetes, and have
provided insights into b cell physiology, insulin release, and the
action of insulin on target cells [6].
Much effort has been devoted to finding common T2D genes,
including genome-wide linkage, candidate-gene, and genome-wide
association studies (GWAS). Whole-genome linkage scans have
identified chromosomal regions linked to T2D; however, with the
exception of regions 1q [7–13] and 20q, which have been
repeatedly mapped, linkage results vary from study to study
[14–19]. Candidate-gene studies have provided strong evidence
that common variants in the peroxisome proliferator-activated
receptor-r (PPARG) [20], potassium inwardly-rectifying channel
J11 (KCNJ11) [21–23], transcription factor 2 isoform b (TCF2)
[24,25], and Wolfram syndrome 1 (WFS1) [26] genes are
associated with T2D. These genes all have strong biological links
to diabetes, and rare, severe mutations cause monogenic diabetes.
GWAS have accelerated the identification of T2D susceptibility
genes, expanding the list from three in 2006 to over 20 genes in
2009. There are now at least 19 loci containing genes that increase
risk of T2D, including PPARG [27], KCNJ11 [27], KCNQ1 [28,29],
PLoS Genetics | www.plosgenetics.org 1 February 2010 | Volume 6 | Issue 2 | e1000847CDKAL1 [27,29–33], CDKN2A-2B [27,32,33], CDC123-CAMK1D
[34], MTNR1B [35–37], TCF7L2 [31,38,39], TCF2 (HNF1B),
HHEX-KIF11-IDE [27,32,33,38], JAZF1 [34], IGF2BP2
[27,29,32], SLC30A8 [27,32,33,38], THADA [34], ADAMTS9 [34],
WFS1 [26], FTO [27,31], NOTCH2 [34], and TSPAN8 [34].
Variants in these genes have been identified almost exclusively in
populations of European descent, except for KCNQ1; individually,
these variants confer a modest risk (odds ratio [OR]=1.1–1.25) of
developing T2D. KCNQ1 was identified as a T2D susceptibility
gene in three GWA scans in Japanese individuals, highlighting the
need to extend large-scale association efforts to different
populations, such as Asian populations [28,29,40]. The association
of other previously reported loci (CDKAL1, CDKN2A-2B, IGF2BP2,
TCF7L2, SLC30A8, HHEX, and KCNJ11) with T2D were also
replicated in the Japanese population [29,40,41].
To date, a GWA scan for T2D has not been conducted in the
Han Chinese population, although the association of some known
loci have been confirmed, including KCNQ1 and CDKAL1,
CDKN2A-2B, MTNR1B, TCF7L2, HNF1b, and KCNJ11 [42–47].
Therefore, we conducted a two-stage GWA scan for T2D in a
Han Chinese population residing in Taiwan. There were a total of
2,798 cases and 2,367 normal controls (995 cases and 894 controls
in stage 1, 1,803 cases and 1,473 controls in stage 2). Our
accomplished objective was to identify new diabetes susceptibility
loci that were associated with increased risk of T2D in a Han
Chinese population.
Results
Association analysis
We conducted a two-stage GWAS to identify genetic variants
for T2D in the Han-Chinese residing in Taiwan. In the first stage,
an exploratory genome-wide scan, we genotyped 995 T2D cases
and 894 population controls using the Illumina Hap550duov3
chip (Figure 1 and Table S1). For each sample genotyped in this
study, the average call rate was 99.9260.12%. After applying
stringent quality control criteria, high-quality genotypes for
516,737 SNPs (92.24%) were obtained, with an average call rate
Author Summary
Type 2 diabetes (T2D) is a complex disease that involves
many genes and environmental factors. Genome-wide and
candidate-gene association studies have thus far identified
at least 19 regions containing genes that may confer a risk
for T2D. However, most of these studies were conducted
with patients of European descent. We studied Chinese
patients with T2D and identified two genes, PTPRD and
SRR, that were not previously known to be involved in
diabetes and are involved in biological pathways different
from those implicated in T2D by previous association
reports. PTPRD is a protein tyrosine phosphatase and may
affect insulin signaling on its target cells. SRR encodes a
serine racemase that synthesizes D-serine from L-serine.
Both D-serine (coagonist) and the neurotransmitter
glutamate bind to NMDA receptors and trigger excitatory
neurotransmission in the brain. Glutamate signaling also
regulates insulin and glucagon secretion in pancreatic
islets. Thus, SRR and D-serine, in addition to regulating
insulin and glucagon secretion, may play a role in the
etiology of T2D. Our study suggests that, in different
patient populations, different genes may confer risks for
diabetes. Our findings may lead to a better understanding
of the molecular pathogenesis of T2D.
Figure 1. Graphical summary of T2D GWAS in a Han Chinese population. T2D association was determined for SNPs on the Illumina
HumanHap550K-Duo chip. The y-axis represents the 2log10 P value and the x-axis represents each of the 516,212 SNPs used in the primary scan of
995 T2D cases and 894 controls.
doi:10.1371/journal.pgen.1000847.g001
Type 2 Diabetes in Han Chinese
PLoS Genetics | www.plosgenetics.org 2 February 2010 | Volume 6 | Issue 2 | e1000847of 99.9260.24% (Table S2). The results of principal component
analysis in stage 1 revealed no evidence for population
stratification between T2D cases and controls (P=0.111, Fst
statistics between populations ,0.001) (Text S1; Figure S1).
Multidimensional scaling analysis using PLINK [48] produced
similar results (Text S1; Figure S2). Furthermore, genomic control
(GC) with a variance inflation factor l=1.078 (trend test) did not
substantially change the results of this GWAS (Table S3).
We selected eight SNPs in seven regions: rs9985652 and
rs2044844 on 4p13, rs7192960 on 16q23.1, rs7361808 on 20p13,
rs1751960 on 10q11.23, rs4845624 on 1q21.3, rs391300 on
17p13.3, and rs648538 on 13q12.3. These SNPs had association P
values of ,10
25 at stage 1 with any of the genotype, allele, trend,
dominant, and recessive models for subsequent cross-platform
validation using Sequenom (Table 1; Table S3). For SNPs with
weaker associations (P value between 10
24 and 10
25), we searched
for novel susceptibility candidates for T2D as implicated by (1)
gene function identified by a bioinformatics approach and (2) an
animal model showing defects in glucose homeostasis caused by
genes within the same subfamily. Therefore, we selected SNP
rs17584499 (P=2.4610
25 under best model) for further investi-
gation. rs17584499 lies within protein tyrosine phosphatase
receptor type D (PTPRD). We hypothesized that PTPRD might
play a role in the regulation of insulin signaling, because its
subfamily members leukocyte common antigen-related (LAR) and
protein tyrosine phosphatase sigma (PTPRS) exhibit defects in
glucose homeostasis and insulin sensitivity in knockout and/or
transgenic mice [49–51].
We also evaluated the most significant SNP (rs231361) within
KCNQ1, which was previously reported to be a diabetes
susceptibility gene in a Japanese population, as well as in
populations of Korean, Chinese, and European ancestry [28,29].
Table 1. Association results for Type 2 diabetes in Han Chinese.
Joint anaysis of stage1+2
SNP
a Chr.
Nearest
gene(s)
Risk
allele stage
RAF
(T2D)
RAF
(NC) OR (95% CI)
P value
(trend) OR (95% CI)
P value
(trend)
P value
(perm)
P value
(Fisher)
rs9985652 4 ATP8A1 A 1 0.54 0.48 1.25 (1.10–1.42) 9.30610
24
GRXCR1 2 0.51 0.52 0.95 (0.86–1.05) 0.316 1.05 (0.97–1.14) 0.193 0.156 0.003
rs2044844 4 ATP8A1 C 1 0.53 0.48 1.24 (1.09–1.41) 9.30610
24
GRXCR1 2 0.51 0.52 0.96 (0.87–1.06) 0.406 1.06 (0.98–1.14) 0.17 0.141 0.003
rs7192960 16 MAF C 1 0.75 0.68 1.39 (1.20–1.61) 7.66610
26
WWOX 2 0.73 0.70 1.12 (1.01–1.25) 0.037 1.21 (1.11–1.33) 1.33610
25 6.82610
26 4.61610
26
rs7361808 20 SIRPA G 1 0.09 0.06 1.60 (1.24–2.05) 2.30610
24
2 0.06 0.06 1.07 (0.87–1.31) 0.52 1.25 (1.07–1.47) 0.005 0.005 0.001
rs1751960 10 LYZL1 G 1 0.53 0.46 1.34(1.18–1.53) 1.13610
25
SVIL 2 0.50 0.49 1.05(0.95–1.16) 0.317 1.15(1.06–1.24) 3.78610
24 4.05610
24 4.85610
25
rs4845624 1 RORC A 1 0.65 0.58 1.36 (1.19–1.56) 5.85610
26
TMEM5 2 0.61 0.63 0.91 (0.83–1.01) 0.07 1.05 (0.97–1.14) 0.205 0.203 6.46610
26
rs391300 17 SRR G 1 0.69 0.63 1.31 (1.14–1.50) 9.00610
25
2 0.68 0.62 1.26 (1.14–1.40) 6.55610
26 1.28 (1.18–1.39) 3.06610
29 1.00610
28 5.52610
28*
rs4523957
b 17 SRR T 1 0.71 0.65 1.30 (1.12–1.49) 3.24610
24
2 0.68 0.63 1.26 (1.14–1.40) 8.22610
26 1.27 (1.17–1.38) 1.44610
28 3.00610
28 1.31610
28*
rs648538 13 KATNAL1 G 1 0.67 0.61 1.28 (1.12–1.47) 2.92610
24
2 0.65 0.66 0.96 (0.86–1.06) 0.407 1.07(0.98–1.16) 0.116 0.125 0.001
rs17584499 9 PTPRD T 1 0.11 0.07 1.55 (1.23–1.94) 1.41610
24
2 0.09 0.06 1.61 (1.33–1.95) 9.15610
27 1.57 (1.36–1.82) 8.54610
210 1.00610
28 3.07610
29*
rs231361 11 KCNQ1 T 1 0.85 0.81 1.39 (1.17–1.64) 1.49610
24
2 0.83 0.79 1.26 (1.11–1.44) 2.85610
24 1.30 (1.18–1.44) 2.89610
27 3.10610
27 7.64610
27*
rs231359
b 11 KCNQ1 A 1 0.85 0.81 1.36 (1.14–1.61) 4.56610
24
2 0.84 0.80 1.32 (1.17–1.51) 1.68610
25 1.33 (1.20–1.48) 3.43610
28 5.00610
28 1.51610
27*
rs2237895
c 11 KCNQ1 C 1 0.40 0.35 1.28 (1.12–1.46) 2.92610
24
2 0.39 0.33 1.30 (1.17–1.45) 6.46610
27 1.29 (1.19–1.40) 9.65610
210 1.00610
28 4.42610
29*
aSNPs are arranged in order of decreasing P value under best statistical model in Stage 1.
bNeighboring SNPs also significantly associated with T2D.
cPreviously reported SNP associated with T2D
28, 29 and validated in our study.
*Empirical P value ,10
6 after 10
8 permutations.
Stage 1(Genome scan) included 995 cases and 894 controls. Stage 2 (replication stage) included 1,803 cases and 1,473 controls. Alleles were indexed to the forward
strand of NCBI Build 36. P value (trend), P value (PC), P value (permutation), and P value (meta) represent P values of trend test, principal component analysis using
EIGENSTRAT, permutation, and meta-analysis using Fisher’s method, respectively.
Risk allele, allele with higher frequency in cases compared to controls; RAF (T2D) and RAF (NC), risk allele frequencies in cases and controls, respectively; and OR, odds
ratio for risk allele.
doi:10.1371/journal.pgen.1000847.t001
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rs17584499, and rs231361—were cross-platform validated and
yielded consistent results using both Illumina and Sequenom. The
concordance rate for stage 1 samples typed on the Illumina and
Sequenom platforms was 99.1%60.84% (Table S4).
We took these ten SNPs and an additional 29 neighboring SNPs
within the linkage disequilibrium (LD) block forward to replicate
in 3,803 additional samples (stage 2; 1,803 cases and 1,473
controls). The average call rate for each sample was
96.13%64.66%. After applying stringent quality control criteria,
high-quality genotypes for 35 SNPs (89.7%) were obtained, with
an average call rate of 98.96%60.24% (Table S2). Of the ten
SNPs selected in stage 1, only three SNPs still showed a strong
association in the stage 2 analysis: rs17584499 in PTPRD at
9p24.1-p23, rs231359 in KCNQ1 at 11p15.5, and rs391300 in
serine racemase (SRR) at 17p13.3 (Table 1). We were unable to
replicate the association between T2D and the remaining seven
SNPs in ATP8A1/GRXCR1, MAF/WWOX, SIRPA, LYZL1/SVIL,
RORC/TMEM5, and KATNAL1 in the stage 2 analysis (Table 1).
Joint analysis of stage 1 and stage 2 data revealed consistent results
with stage 2. The most significant associations were found for
rs391300, rs17584499, and rs231359 (Table 1; Figure 2). These
associations remained significant after calculating P values using
10
8 permutations of the disease state labels. Joint association
analysis was performed with all of the 2,798 T2D cases and 2,367
controls; this could achieve a power of 0.85 to detect a disease
allele with a frequency of 0.15 and an OR of 1.5, assuming a
disease prevalence of 0.06, at a significant level of 0.05 (Table S5).
Identification of two novel T2D loci and confirmation of
KCNQ1 association
Two previously unknown loci were detected in our joint analysis
of GWAS data. The strongest new association signal was found for
rs17584499 in intron 10 of PTPRD (P=8.54610
210 [trend test];
allelic OR=1.57, 95% confidence interval [CI]=1.36–1.82)
(Table 1; Figure 2). The second strongest signal was found with
rs391300 (P=3.06610
29 [trend test]; OR=1.28, 95% CI=1.18–
1.39). The nearby SNP rs4523957 also demonstrated a significant
association (P=1.44610
28; OR=1.27, 95% CI=1.17–1.38).
SNPs rs391300 and rs4523957 were in tight LD with one another
(r
2=0.942 in HapMap HCB), and were located within the serine
racemase gene (SRR).
SNP rs231361, located in intron 11 of KCNQ1, had a less
significant association with T2D, and was selected in stage 1
(P=1.49610
24 [trend test]; OR=1.39, 95% CI=1.17–1.64)
(Table 1). We further genotyped eight additional SNPs within the
same LD block from the HapMap Asian group data: rs231359
yielded a P value of 4.56610
24 with a trend test (OR=1.36, 95%
CI=1.14–1.61) (Figure 2). rs231361 and rs231359 were in strong
LD with one another (r
2=1 in HapMap HCB), and were located
approximately 164 kb upstream of SNP rs2237897, which was
previously reported to be significantly associated with T2D in a
Japanese population [28,29]. We took rs231361, rs231359, and
neighboring SNPs within the LD block forward to replicate in
stage 2. Joint analysis of stage 1 and stage 2 data revealed that
rs231359 had an even stronger association with T2D than did
rs231361 (rs231359: P=3.43610
28, OR=1.33, 95% CI=1.2–
1.48; rs231361: P=2.89610
27, OR=1.3, 95% CI=1.18–1.44).
Additional SNPs that were reported to be significantly associated
with T2D in a Japanese population were further genotyped [28,29].
The average call rate for each sample was 99.12%67.21%. After
applying stringent quality control criteria, we obtained high-quality
genotypes with an average call rate of 99.16%60.18% (Table S2).
SNPrs2237895showedthestrongestassociationwithT2Dofallthe
genotyped SNPs in KCNQ1 (P=9.65610
210; OR=1.29, 95%
CI=1.19–1.40) (Figure 2 and Figure S3; Table S6). Conditioning
on the rs2237895, the statistical significance of rs231361 (or
rs231359) disappeared. It seems the same underlying biological
effect between the 2 SNPs (Table S7).
Subsequently, we sequenced all of the exons, intron–exon
boundaries, and up to 1.2 kb of the promoter region of the KCNQ1
Figure 2. Regional plots of three significant associations. For
each of the (A) PTPRD, (B) SRR, and (C) KCNQ1 regions, the 2log10 P
values for the trend test from the primary scan were plotted as a
function of genomic position (NCBI Build 36). The SNPs with the
strongest signal and neighboring genotyped SNPs in the joint analysis
are denoted by blue diamonds. Green diamonds in the KCNQ1 region
(C) represent reported T2D–associated SNPs genotyped in all samples
of joint analysis. Estimated recombination rates (right y-axis) based on
the Chinese HapMap population was plotted to reflect the local LD
structure around the significant SNPs. Gene annotations were taken
from NCBI.
doi:10.1371/journal.pgen.1000847.g002
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variations, including one nonsynonymous P448R polymorphism
and two novel SNPs with minor allele frequency .0.03. We then
genotyped the two novel SNPs and one nonsynonymous
polymorphism; however, none of these SNPs showed an
association with T2D (Table S6).
Discussion
Our GWAS for T2D in a Han Chinese population found two
previously unreported susceptibility genes. All of the significant
variants detected in our study showed modest effects, with an OR
between 1.21 and 1.57. Two loci with less-significant associations
in our primary scan (stage 1), PTPRD and KCNQ1, were selected
for further replication; both showed compelling evidence of
association in joint analysis. The susceptibility loci we identified
in this study need to be further replicated in additional
populations. Of the 18 loci previously reported to be associated
with T2D (with the exception of KCNQ1), none of the P values for
any of the SNPs within or near the genes reached 10
25 using
allele, genotype, trend, dominant, or recessive models (Table S8;
Figure S4). Three SNPs within CDKAL1, JAZF1, and HNF1B had
the lowest P values, ranging from 5610
24 to 10
25, among the 18
known loci (Table S8). No significant associations were found
within these regions in our Han Chinese population.
The strongest new signal was observed for rs17584499 in
PTPRD. The overall Fst among 11 HapMap groups for
rs17584499 was estimated to be 0.068 [52], which indicated a
significant difference in allele frequencies among the populations
(P,0.0001, chi-square test ) (Table S9). PTPRD is widely
expressed in tissues, including skeletal muscle and pancreas, and
is expressed highest in the brain. PTPRD-deficient mice exhibit
impaired learning and memory, early growth retardation,
neonatal mortality, and posture and motor defects [53]. Multiple
mRNA isoforms are expressed by alternative splicing and/or
alternative transcription start sites in a developmental and tissue-
specific manner [54,55]. PTPRD belongs to the receptor type IIA
(R2A) subfamily of protein tyrosine phosphatases (PTPs). The
R2A PTP subfamily comprises LAR, PTPRS, and PTPRD. The
R2A family has been implicated in neural development, cancer,
and diabetes [56]. Although the complex phenotype including
neurological defects seen in knockout mice could obscure the roles
of these genes in glucose homeostasis, LAR- and PTPRS-deficient
mice were demonstrated to have altered glucose homeostasis and
insulin sensitivity [49–51]. Transgenic mice overexpressing LAR in
skeletal muscle show whole-body insulin resistance [57]. Because
R2A subfamily members are structurally very similar [54], PTPRD
could play a role in T2D pathogenesis and should be further
characterized.
The second new association locus was found for rs391300 and
rs4523957 in the biologically plausible candidate gene SRR. SRR
encodes a serine racemase that synthesizes D-serine from L-serine
[58,59]. D-serine is a physiological co-agonist of the N-methyl D-
aspartate (NMDA) class of glutamate receptors, the major
excitatory neurotransmitter receptors mediating synaptic neuro-
transmission in the brain [60,61]. NMDA receptor activation
requires binding of glutamate and D-serine, which plays a
neuromodulatory role in NMDA receptor transmission, synaptic
plasticity, cell migration, and neurotoxicity [62]. D-serine and
SRR are also present in the pancreas [63]. Glutamate signaling
functions in peripheral tissues, including the pancreas, and
positively modulates secretion of both glucagon and insulin in
pancreatic islets [64–66]. The nearby SNP rs216193 also showed
significant association (P=2.49610
26); this SNP resides 3.8 kb
upstream from SRR, within Smg-6 homolog, nonsense mediated
mRNA decay factor (C. elegans)( SMG6). rs216193 was in tight LD
with rs391300 (r
2=0.942 in HapMap HCB). Based on their
biological functions and the association results, neither SMG6 nor
any of the nearby genes TSR1, SGSM2, MNT, and METT10D
were compelling candidates for association withT2D. However,
SRR was significantly associated with T2D; thus, we suggest that
dysregulation of D-serine could alter glutamate signaling and
affect insulin or glucagon secretion in T2D pathogenesis.
rs7192960 also had a suggestive association with T2D
(P=1.32610
25; OR=1.21, 95% CI=1.11–1.33). This SNP
which lies approximately 211 kb downstream of v-maf musculo-
aponeurotic fibrosarcoma oncogene homolog (avian) (MAF) and
170 kb downstream of WW domain containing oxidoreductase
(WWOX). WWOX is a tumor suppressor gene that spans the
second most common human fragile site FRA16D [67,68], and is
disrupted in many tumors, including pancreatic carcinoma
[67,69–73]. MAF encodes the transcription factor c-Maf, a
member of the Maf family of basic-Zip (bZip) transcription
factors. c-Maf is involved in development and differentiation of the
lens [74,75], kidney [76], immune system [77], adipose tissue [78],
and pancreas [79]. It is expressed in a cells of the pancreatic islets
[80], and is a strong transactivator of the glucagon promoter that
regulates glucagon gene expression [80,81]. c-Maf is also
associated with early-onset and morbid adult obesity [82].
Our GWAS revealed that KCNQ1, which was previously
reported to be associated with T2D in several populations, was
also associated with T2D in a Han Chinese population residing in
Taiwan. KCNQ1 encodes the pore-forming a subunit of a voltage-
gated K
+ channel (KvLQT1), which is involved in repolarization
of the action potential in cardiac muscle [83,84]. Mutations in
KCNQ1 cause long QT syndrome [85,86] and familial atrial
fibrillation [87]. KCNQ1 is widely expressed, including in the heart,
brain, kidney, liver, intestine, and pancreas [88–90]. It is also
expressed in pancreatic islets, and blockade of the KvLQT1
channel stimulates insulin secretion in insulin-secreting INS-1 cells
[91]. KCNQ1 knockout mice have cardiac dysfunctions [88,92] and
enhanced systemic insulin sensitivity [93]. In our study, variants in
the coding region did not show an association with T2D. The
functional variant(s) could be located in the regulatory element of
KCNQ1, rather than in the coding region. We did not find an
association between either CDKAL1 or IGF2BP2 and T2D, in
contrast with the results described in a previous study [29], nor did
we find T2D associated with various other genes identified in
populations of European descent.
In conclusion, we identified two previously unknown loci that
are associated with T2D in a Han Chinese population, and
confirmed the reported association of KCNQ1 with T2D. The
novel T2D risk loci may involve genes that are implicated in
insulin sensitivity and control of glucagon and insulin secretion:
PTPRD may participate in the regulation of insulin action on its
target cells, while SRR variants may alter glutamate signaling in
the pancreas, thus regulating insulin and/or glucagon secretion.
Our study suggests that in different patient populations, different
genes may confer risks for diabetes, which may lead to a better
understanding of the molecular pathogenesis of T2D.
Materials and Methods
Ethical statement
The study was approved by the institutional review board and
the ethics committee of each institution. Written informed consent
was obtained from each participant in accordance with institu-
tional requirements and the Declaration of Helsinki Principles.
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A total of 2,798 unrelated individuals with T2D, age .20 years,
were recruited from China Medical University Hospital (CMUH),
Taichung, Taiwan; Chia-Yi Christian Hospital (CYCH), Chia-Yi,
Taiwan; and National Taiwan University Hospital (NTU), Taipei,
Taiwan. All of the T2D cases were diagnosed according to medical
records and fasting plasma glucose levels using American Diabetic
Association Criteria. Subjects with type 1 diabetes, gestational
diabetes, and maturity-onset diabetes of the young (MODY) were
excluded from this study. For the two-stage GWAS, we genotyped
995 T2D cases and 894 controls in the first exploratory genome-
wide scan (stage 1). In the replication stage (stage 2), we genotyped
selected SNPs in additional samples from 1,803 T2D cases and
1,473 controls. The controls were randomly selected from the
Taiwan Han Chinese Cell and Genome Bank [94]. The criteria
for controls in the association study were (1) no past diagnostic
history of T2D, (2) HbA1C ranging from 3.4 to 6, and (3)
BMI,32. The two control groups were comparable with respect
to BMI, gender, age at study, and level of HbA1C. All of the
participating T2D cases and controls were of Han Chinese origin,
which is the origin of 98% of the Taiwan population. Details of
demographic data are shown in Table S10.
Genotyping
Genomic DNA was extracted from peripheral blood using the
Puregene DNA isolation kit (Gentra Systems, Minneapolis, MN,
USA). In stage 1, whole genome genotyping using the Illumina
HumanHap550-Duo BeadChip was performed by deCODE
Genetics (Reykjavı ´k, Iceland). Genotype calling was performed
using the standard procedure implemented in BeadStudio
(Illumina, Inc., San Diego, CA, USA), with the default parameters
suggested by the platform manufacturer. Quality control of
genotype data was performed by examining several summary
statistics. First, the ratio of loci with heterozygous calls on the X
chromosome was calculated to double-check the subject’s gender.
Total successful call rate and the minor allele frequency of cases
and controls were also calculated for each SNP. SNPs were
excluded if they: (1) were nonpolymorphic in both cases and
controls, (2) had a total call rate ,95% in the cases and controls
combined, (3) had a minor allele frequency ,5% and a total call
rate ,99% in the cases and controls combined, and (4) had
significant distortion from Hardy–Weinberg equilibrium in the
controls (P,10
27). Genotyping validation was performed using
the Sequenom iPLEX assay (Sequenom MassARRAY system;
Sequenom, San Diego, CA, USA). In the replication stage (stage
2), SNPs showing significant or suggestive associations with T2D
and their neighboring SNPs within the same LD block were
genotyped using the Sequenom iPLEX assay. The neighboring
SNPs in the same LD were selected from the HapMap Asian
(CHB + JPT) group data for fine mapping the significant signal.
Statistical analysis
T2D association analysis was carried out to compare allele
frequency and genotype distribution between cases and controls
using five single-point methods for each SNP: genotype, allele,
trend (Cochran–Armitage test), dominant, and recessive models.
The most significant test statistic obtained from the five models
was chosen. SNPs with P values less than a=2610
28, a cut-off for
the multiple comparison adjusted by Bonferroni correction, were
considered to be significantly associated with the traits. The joint
analysis was conducted by combining the data from the stage 1
and 2 samples. We also applied Fisher’s method to combine P
values for joint analysis. The permutation test was carried out
genome-wide for 10
6 permutations, in which the phenotypes of
subjects were randomly rearranged. For better estimation of
empirical P values, the top SNPs were reexamined using 10
8
permutations. Each permutation proceeded as follows: (1) the case
and control labels were shuffled and redistributed to subjects, and
(2) the test statistics of the corresponding association test was
calculated based on the shuffled labels. The empirical P value was
defined as the number of permutations that were at least as
extreme as the original divided by the total number of
permutations. Detection of possible population stratification that
might influence association analysis was carried out using principle
component analysis, multidimensional scaling analysis, and
genomic control (Text S1). Quantile–quantile (Q–Q) plots were
then used to examine P value distributions (Figure 3 and Figure
S5).
Supporting Information
Figure S1 Principle component analysis (PCA) plot. The PCA
plot shows the first two principal components, estimated by
EIGENSTRAT (Price et al. Nat Genet 38: 904–909), based on
genotype data from 76,673 SNPs with equal spacing across the
human genome. No population stratification between the 995
Figure 3. Q–Q plot for the trend test. Q–Q plots are shown for the trend test based on the 516,212 quality SNPs of the initial analysis of 995 cases
and 894 controls. The red lines represent the upper and lower boundaries of the 95% confidence bands.
doi:10.1371/journal.pgen.1000847.g003
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(P=0.111, and Fst statistics between populations ,0.001).
Found at: doi:10.1371/journal.pgen.1000847.s001 (1.18 MB
TIF)
Figure S2 Multidimensional scaling analysis (MDS) plot. The
MDS plot shows the first two principal components, estimated by
PLINK (Zheng et al. Am J Hum Genet 81:559–575), based on
genotype data from 516,212 SNPs. No population stratification
between the 995 T2D cases (red) and 894 controls (blue) was
detected (IBS group-difference empirical P=0.192598 for T1:
case/control less similar).
Found at: doi:10.1371/journal.pgen.1000847.s002 (0.74 MB
TIF)
Figure S3 LD block between rs231361 and rs223787.
Found at: doi:10.1371/journal.pgen.1000847.s003 (0.17 MB
TIF)
Figure S4 Comparisons to susceptible regions reported by
previous GWAS. For each of the (A) NOTCH2, (B) THADA, (C)
PPARG, (D) IGF2BP2, (E) ADAMTS9, (F) WFS1, (G) CDKAL1, (H)
JAF1, (I) SLC30A8, (J) CDKN2AB, (K) HHEX, (L) CDC123/
CAMK1D, (M) TCF7L2, (N) KCNJ11, (O) MTNR1B, (P) TSPAN8/
LGR5, (Q) FTO, and (R) TCF (HNF1B) regions, the 2log10 P
values from the primary scan are plotted as a function of genomic
position (NCBI Build 36). The reported SNPs in previous GWAS
are denoted by blue diamonds. Estimated recombination rates
(right y-axis) based on the Chinese HapMap population are
plotted to reflect the local LD structure around the significant
SNPs. Gene annotations and numbers of transcripts were taken
from NCBI.
Found at: doi:10.1371/journal.pgen.1000847.s004 (4.17 MB TIF)
Figure S5 Quantile-quantile (QQ) plots. QQ plots are shown for
the four association tests, (A) allelic, (B) genotype, (C) dominant,
and (D) recessive, based on the 516,212 quality SNPs of the initial
analysis of 995 cases and 894 controls. The upper and lower
boundaries of the 95% confidence bands are represented by the
red lines.
Found at: doi:10.1371/journal.pgen.1000847.s005 (3.10 MB TIF)
Table S1 Quality control of the subject participants in stage 1.
Found at: doi:10.1371/journal.pgen.1000847.s006 (0.03 MB
DOC)
Table S2 Quality control of the genotyping results.
Found at: doi:10.1371/journal.pgen.1000847.s007 (0.03 MB
DOC)
Table S3 Association results in stage 1.
Found at: doi:10.1371/journal.pgen.1000847.s008 (0.05 MB
DOC)
Table S4 Concordance rates for the 10 SNPs with significant
associations in stage 1.
Found at: doi:10.1371/journal.pgen.1000847.s009 (0.05 MB
DOC)
Table S5 Power Calculation using CaTS.
Found at: doi:10.1371/journal.pgen.1000847.s010 (0.05 MB
DOC)
Table S6 Association of additional SNPs within KCNQ1 in all
T2D cases and controls in the joint analysis.
Found at: doi:10.1371/journal.pgen.1000847.s011 (0.06 MB
DOC)
Table S7 Conditional analysis on rs2237895.
Found at: doi:10.1371/journal.pgen.1000847.s012 (0.03 MB
DOC)
Table S8 Previously reported loci and SNPs associated with
T2D.
Found at: doi:10.1371/journal.pgen.1000847.s013 (0.13 MB
DOC)
Table S9 Genotype frequency and allele frequency of
rs17584499 (founders only) from HapMap3.
Found at: doi:10.1371/journal.pgen.1000847.s014 (0.05 MB
DOC)
Table S10 Clinical characteristics of the subjects.
Found at: doi:10.1371/journal.pgen.1000847.s015 (0.04 MB
DOC)
Text S1 Supplementary methods.
Found at: doi:10.1371/journal.pgen.1000847.s016 (0.03 MB
DOC)
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